Table 2.

Clinical and biochemical values at baseline and weeks 16, 52, and 104 among patients with Crohn’s disease treated with ustekinumab

	Baseline	Week 16	Week 52	Week 104	Week 16	Week 52	Week 104
	Median (IQR)				Median change vs. baseline* (IQR); p-value
HBI	6 (4–11) (n = 96)	5 (4–7) (n = 80)	4 (2–6) (n = 66)	3 (1–5) (n = 49)	− 1 (− 3–1); .003 (n = 70)	− 2 (− 4– − 1); < .001 (n = 56)	− 2 (− 5–0); < .001 (n = 43)
CRP mg/l	7 (4–15) (n = 98)	5 (4–7) (n = 75)	4 (4–6) (n = 65)	4 (4–6) (n = 48)	− 1 (− 9–0); .006 (n = 65)	− 1 (− 10–0); < .001 (n = 54)	− 1 (− 7–0); < .001 (n = 39)
F-calprotectin µg/g	292 (163–1143) (n = 37)	204 (134–367) (n = 46)	191 (58–527) (n = 52)	139 (58–441) (n = 50)	− 65 (− 754–19); .02** (n = 18)	− 86 (− 548–113); .1** (n = 15)	− 14 (− 112–318); .4** (n = 15)
Hb g/l	135 (125–146) (n = 99)	138 (128–149) (n = 75)	140 (130–146) (n = 66)	134 (127–147) (n = 49)	0 (− 4–7); .3 (n = 66)	2 (− 4–10); .07 (n = 55)	− 2 (− 8–6); .8 (n = 41)

HBI = Harvey–Bradshaw Index; CRP = C-reactive protein; f-calprotectin = fecal calprotectin; Hb = hemoglobin; IQR, inter-quartile range; n = number of patients with available data within ± 2 weeks of baseline, weeks 16, 52, and 104 visits to the physician

*Includes patients with recorded data at baseline ± 2 weeks and at weeks 16, 52, and 104 ± 2 weeks; ** calculated as ln(f-calprotectin)